Veterinary Cardiology Market Forecast: Navigating the Next Decade of Growth

 The global veterinary cardiology market was valued at USD 2,787.0 million in 2024 and is projected to reach USD 4,468.3 million by 2030, reflecting a CAGR of 8.4% from 2025 to 2030. A significant driver for this market is the high prevalence of cardiological disorders among companion animals, especially dogs.

 

Research indicates that approximately 10% of all dogs seen in primary care veterinary settings are diagnosed with heart disease, with this figure escalating to over 60% in older dogs. Among these cases, myxomatous mitral valve disease (MMVD) is the most prevalent, accounting for 75% of canine heart disease cases in the U.S., primarily affecting the heart valves. Another important condition, dilated cardiomyopathy (DCM), directly affects the heart muscle. The widespread occurrence of these disorders highlights the increasing demand for advanced diagnostics, therapeutics, and specialized animal care, which in turn fuels the growth of the veterinary cardiology market.

 

Additionally, the rising awareness of preventive health care has led pet owners to invest more in their pets' health to enhance their overall well-being. The increasing spending on animal care is a notable factor driving market growth. According to an article published in February 2024 by the Bureau of Labor Statistics, the cost of veterinary services surged by 7.5% from September 2022 to September 2023. This trend is indicative of growing pet ownership, heightened awareness of pet health, and advancements in veterinary diagnostics and treatments. As pet owners prioritize specialized care, including cardiology services, this surge in spending underpins the demand for innovative solutions and expanded offerings in animal cardiology.

 

Key Market Trends & Insights

• North America: North America led the overall global veterinary cardiology market, capturing the largest revenue share of 38.48% in 2024. This dominance is attributed to advanced veterinary healthcare infrastructure, high pet ownership rates, and increasing awareness of animal health issues. The region's robust research and development activities further contribute to the availability of cutting-edge diagnostic and therapeutic options, making it a pivotal area for market growth. 

• Asia Pacific: The Asia Pacific region is anticipated to exhibit the fastest compound annual growth rate (CAGR) from 2025 to 2030. This growth is driven by rising disposable incomes, increasing pet ownership, and heightened awareness of pet health among consumers. Furthermore, the expansion of veterinary clinics and hospitals, along with improved access to advanced veterinary care, will support the market's rapid growth in this region. 

• Companion Animals Segment: The companion animals segment dominated the market, accounting for over 67.28% of the total market share in 2024. This significant share reflects the growing trend of pet humanization, where pet owners view their animals as family members and prioritize their health and well-being. Increased spending on veterinary care, especially for dogs and cats, is a critical factor driving the expansion of this segment. 

• Congestive Heart Failure Segment: By indication, the congestive heart failure segment held a substantial market share of over 37.93% in 2024. This segment's dominance is primarily due to the high incidence of heart disease in older companion animals, particularly dogs. As veterinarians increasingly recognize the importance of early diagnosis and management of cardiac conditions, an increasing number of treatment options are being developed, further enhancing this segment's growth prospects. 

• Pharmaceuticals Segment: The pharmaceuticals segment emerged as the leading product category in 2024, reflecting its vital role in managing cardiological disorders in animals. This includes medications for heart failure, arrhythmias, and other cardiac conditions. The ongoing development of novel therapeutics and the increasing availability of specialized veterinary medications are key factors propelling the growth of this segment. Furthermore, pet owners’ willingness to invest in high-quality healthcare products for their pets reinforces the market's expansion.

 

Order a free sample PDF of the Veterinary Cardiology Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 2,787.0 Million
• 2030 Projected Market Size: USD 4,468.3 Million
• CAGR (2025-2030): 8.4%
• North America: Largest market in 2024

 

Key Players

• Boehringer Ingelheim International GmbH
• Jurox Pty Limited
• Ceva
• Merck & Co., Inc.
• IDEXX
• Apex Bio Medical
• SOUND
• General Electric Company
• FUJIFILM Holdings America Corporation
• ESAOTE SPA

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The veterinary cardiology market is on an upward trajectory, driven by the increasing incidence of heart disease in companion animals, particularly dogs. The market is supported by rising pet ownership and a greater focus on preventive health care, reflected in the growing expenditure on veterinary services. As more pet owners seek specialized cardiology care, the demand for advanced diagnostics and therapeutics will likely continue to expand, providing significant opportunities for growth within the market.

Wound Closure Devices Market Insights: Addressing Demand for Quick, Aseptic, and Scar-Minimizing Closure Solutions

 The global wound closure devices market was valued at an estimated USD 14.43 billion in 2024 and is projected to reach USD 21.15 billion by 2030. This expansion corresponds to a Compound Annual Growth Rate (CAGR) of 6.60% over the forecast period from 2025 to 2030.

This robust growth is primarily fueled by several factors: the increasing volume of surgical procedures and accidental injuries, the rising prevalence of chronic wounds (such as diabetic foot ulcers and pressure ulcers), and the expanding geriatric population, which is more susceptible to these conditions.

 

Key Market Trends & Insights

• North America accounted for the largest revenue share of 38.48% in the wound closure devices market in 2024, driven by ongoing research in the wound care sector and an increase in product launches.
• The wound closure devices market in Europe is projected to grow at a CAGR of 8.95% in the forthcoming years.
• In terms of product segmentation, the sutures segment led the market, capturing over 40.00% of the revenue share in 2024. This strong performance is due to the proven effectiveness, versatility, and acceptance of sutures across various medical applications.
• By end use, the hospitals segment dominated with a revenue share of 39.44% in 2024, attributed to the rising number of surgical procedures and trauma incidents. The increase in chronic diseases and accidents is leading hospitals to experience a higher influx of patients needing effective wound management solutions.
• Regarding wound type, the acute wounds segment led the market in 2024 and is expected to maintain its dominance with the highest CAGR of 7.17% throughout the forecast period. This growth is linked to a rise in traumatic injuries and surgical interventions.

 

Order a free sample PDF of the Wound Closure Devices Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 14.43 Billion
• 2030 Projected Market Size: USD 21.15 Billion
• CAGR (2025-2030): 6.60%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

The market features major companies such as 3M, Ethicon (Johnson & Johnson Services, Inc.), Medtronic, Baxter, Smith+Nephew, and Stryker. These key players are actively focusing on product launches, such as the example from Corza Medical, to gain a competitive advantage and meet the expanding global need for effective wound management solutions.

 

Key Players

• 3M
• Ethicon (Johnson & Johnson Services, Inc.)
• Medtronic
• Baxter
• Smith+Nephew
• Stryker
• Advanced Medical Solutions Group plc
• Riverpoint Medical
• DermaClip
• AVITA Medical, Inc.
• Corza Medical

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The wound closure devices market is set for considerable growth, with projections indicating an increase from USD 14.43 billion in 2024 to USD 21.15 billion by 2030 at a 6.60% CAGR. This upward trend is critically underpinned by the global rise in surgical procedures, an aging population, and the escalating burden of chronic conditions like diabetes, which leads to complex chronic wounds. Continuous technological innovation and product acceptance (with sutures dominating and hospitals being the key end-use segment) ensure that the market will continue to expand to address the universal need for rapid, safe, and effective wound management.

Vaccine Adjuvants Market Innovation: Focusing on Enhanced Efficacy, Durability, and Dose Reduction

 The global market for vaccine adjuvants was valued at an estimated USD 3.81 billion in 2024 and is projected to reach USD 4.86 billion by 2030. This anticipated growth represents a Compound Annual Growth Rate (CAGR) of 4.32% over the period from 2025 to 2030.

The market's expansion is fundamentally driven by two factors: the increasing necessity for highly effective vaccines to combat the threat of emerging and re-emerging infectious diseases, and the growing prevalence of chronic conditions, particularly cancer.

 

Key Market Trends & Insights

• Enhanced Immune Performance: The growing recognition of adjuvants' integral role in significantly improving the efficacy, durability, and breadth of immune responses is accelerating their incorporation into both preventive (prophylactic) and therapeutic vaccines.
• Next-Generation Development: Advances in molecular biology and immunology are leading to the creation of advanced adjuvants, such as saponin-based adjuvants and Toll-Like Receptor (TLR) agonists. These innovations are designed to target specific immune pathways, offering superior safety and effectiveness profiles. This progress addresses the critical need for vaccines that can generate robust immune responses with reduced antigen doses, thereby making them more cost-effective and easier to scale.
• Investments and Global Health Initiatives: Market growth is being further fueled by substantial investments in vaccine research and development (R&D) from governments, NGOs (e.g., CEPI and Gavi), and pharmaceutical companies. These initiatives support innovation and expand access to advanced adjuvanted vaccines in low- and middle-income countries.
• Pandemic Focus and New Frontiers: The continuous focus on pandemic preparedness (highlighted by COVID-19 and other outbreaks) has emphasized the demand for adjuvant-enhanced vaccines capable of rapid deployment. Additionally, the potential applications of vaccine adjuvants are broadening into oncology and other therapeutic areas, driven by the industry shift toward precision immunology and personalized medicine.

 

Order a free sample PDF of the Vaccine Adjuvants Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 3.81 Billion
• 2030 Projected Market Size: USD 4.86 Billion
• CAGR (2025-2030): 4.32%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

Key market players, including GSK plc, CSL Seqirus, Novavax, Inc., and Dynavax Technologies Corporation, maintain a strong market position through their established product portfolios and extensive global distribution networks. These companies are actively engaged in R&D for next-generation adjuvants, pursuing strategic collaborations, and expanding their market presence to meet the increasing demand across infectious diseases and therapeutic areas. The intensifying focus on precision immunology and personalized vaccines is expected to reshape competition, creating new opportunities for both established leaders and emerging innovators.

 

Key Players

• GlaxoSmithKline plc.
• Novavax, Inc.
• Adjuvance Technologies, Inc.
• SPI Pharma
• Agenus, Inc.
• CSL Limited
• InvivoGen
• Brenntag Biosector

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The global vaccine adjuvants market is slated for a steady trajectory of growth, forecast to rise from USD 3.81 billion in 2024 to USD 4.86 billion by 2030, reflecting a 4.32% CAGR. This sustained expansion is driven by the indispensable global need for more effective, durable, and scalable vaccines against both infectious diseases and chronic conditions like cancer. Crucial factors propelling this market forward include continuous R&D investment, the success of next-generation adjuvant technologies (e.g., TLR agonists), and the strategic emphasis on pandemic preparedness and emerging therapeutic applications in personalized medicine.

Home Infusion Therapy Market: Impacts of Regulatory Changes and Policies

 The global home infusion therapy market was valued at USD 38.66 billion in 2024 and is projected to grow to USD 61.72 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.2% from 2025 to 2030. Home infusion therapy entails the delivery of treatments, medications, or fluids directly into a patient’s bloodstream via intravenous (IV) infusion, typically within the comfort and convenience of their own home.

 

Several key factors are driving this market's growth, such as the increasing geriatric population with reduced mobility, a rising preference for home care, and rapid technological advancements. Infusion therapy, which includes essential components like IV therapy and IV hydration therapy, is vital for treating conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medications are ineffective. The steadily increasing demand for these therapies is largely due to the necessity for long-term treatment among patients, positioning home infusion therapy as a notably cost-effective alternative to traditional hospital care. By providing IV therapy and hydration services, it enhances patient access to effective and personalized medical solutions from home.

 

A significant factor promoting the adoption of home infusion therapy within global healthcare systems is its cost-effectiveness. Administering IV treatments outside hospital settings drastically reduces expenses linked to inpatient care, such as hospital admissions, re-admissions, and longer stays. This model not only lowers direct treatment costs but also minimizes ancillary expenses, including facility overhead and staffing. Home infusion therapy offers considerable savings compared to conventional inpatient care, making it an appealing option for both patients and healthcare payers. For example, according to the National Home Infusion Association (NHIA), the cost of home infusion therapy ranges from USD 122 to USD 225 per day, whereas inpatient care can vary from USD 586 to USD 798 per day, depending on the type of therapy administered.

 

Key Market Trends & Insights

• North America held the largest market share at 56.6% in 2024, driven by increased R&D and the adoption of new technologies in infusion pumps. The growing need for long-term therapy for patients with specific conditions fuels the regional market.
• The U.S. home infusion therapy market is expected to expand during the forecast period, mainly due to the rise in chronic diseases and the cost-effectiveness of home-based care. Medicare supports home infusion services such as nursing visits, caregiver training, and patient monitoring for certain intravenous or subcutaneous drugs administered at home.
• By type, the services segment dominated the home infusion therapy market, accounting for 72.4% of global revenue in 2024. This dominance is primarily due to the heightened demand for clinical interventions, including anti-infective therapy, parenteral nutrition, chemotherapy, hydration therapy, and pain management within home settings.
• In terms of application, anti-infectives led the market with the highest revenue share in 2024, attributed to the notable number of procedures related to the administration of antifungal and antibiotic medications. This approach also helps minimize patient exposure to other hospital-acquired infections (HAIs).

 

Order a free sample PDF of the Home Infusion Therapy Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 38.66 Billion
• 2030 Projected Market Size: USD 61.72 Billion
• CAGR (2025-2030): 8.2%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

Prominent companies in the home infusion therapy market include Option Care Health, Inc., Baxter, and Fresenius Kabi AG.

• Baxter is a global healthcare company with a diverse range of medical products, therapies, and technologies, evolving into a leading industry player since its inception in the 1930s. The company focuses on innovative solutions for critical medical needs, including renal care, medication delivery, and various therapeutic areas.
• Becton, Dickinson, and Company (BD) is a global medical technology firm specializing in medical devices, laboratory equipment, and diagnostic products that enhance the diagnosis and treatment of various conditions. Committed to healthcare improvement, BD provides solutions in medication management, infection prevention, diagnostics, and biosciences.

 

Key Players

• Baxter
• B. Braun SE
• BD
• Fresenius Kabi AG
• ICU Medical, Inc.
• Terumo Corporation
• JMS Co. Ltd.
• Option Care Health, Inc.
• CareCentrix, Inc.
• Coram LLC.
• PharMerica Corporation
• Moog Inc.
• Amedisys, Inc.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The home infusion therapy market is poised for significant growth due to demographic shifts, technological advancements, and economic benefits associated with home-based care. With increasing demand for long-term treatments, the sector offers a compelling alternative to traditional inpatient therapies, promising both accessibility and affordability for patients globally.

Anticoagulant Reversal Drugs Market: Comprehensive Review of Major Strategies

 The global anticoagulant reversal drugs market was valued at USD 1.38 billion in 2024 and is anticipated to reach USD 2.78 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030. This growth is primarily driven by the increasing incidence of thromboembolic disorders. Additionally, an aging population contributes to a higher prevalence of conditions that require anticoagulation therapy, further driving demand.

 

The rise in elective and emergency surgical procedures also necessitates effective reversal options to manage anticoagulation safely. Furthermore, heightened awareness among healthcare professionals and patients regarding the risks associated with anticoagulants, along with advancements in research and regulatory approvals, supports the overall growth of the market.

 

The aging population significantly contributes to the rising incidence of thromboembolic disorders, as older adults are more vulnerable to conditions such as atrial fibrillation and deep vein thrombosis. Sedentary lifestyles and increasing obesity rates further exacerbate this trend, as they are linked to poor circulation and heightened clotting risks. Additionally, the prevalence of chronic diseases, including heart disease and cancer, plays a crucial role in the occurrence of thromboembolic events. Improved awareness and diagnostic capabilities have led to the identification and reporting of more cases, contributing to the increasing incidence. 

 

Key Market Trends & Insights

• North America: This region dominated the global market, holding a revenue share of 38.6% in 2024. The high prevalence of cardiovascular conditions, particularly atrial fibrillation and venous thromboembolism, necessitates effective anticoagulation therapy to prevent complications such as strokes and blood clots.
• Distribution Channel: Hospital pharmacies led the market with the largest revenue share of 48.6% in 2024, driven by the urgent need for immediate access to anticoagulant reversal agents in emergencies. Hospital pharmacies play a crucial role in direct patient care, with high demand for these drugs during urgent cases like major bleeding or surgical interventions.
• Product Type: The idarucizumab segment dominated the market, accounting for a revenue share of 36.8% in 2024. Its high specificity for dabigatran makes it an effective option for reversing anticoagulation in emergencies, with rapid action crucial in life-threatening situations.

 

Order a free sample PDF of the Anticoagulant Reversal Drugs Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 1.38 Billion
• 2030 Projected Market Size: USD 2.78 Billion
• CAGR (2025-2030): 12.3%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

Key companies operating in this market include Pfizer Inc., AstraZeneca, Dr. Reddy’s Laboratories Ltd., Endo International plc, and Teva Pharmaceutical Industries Ltd. These companies are pursuing strategic initiatives such as mergers, acquisitions, and product launches to expand their market presence and meet evolving healthcare demands through anticoagulant reversal drugs.

• Pfizer Inc.: Offers a range of products in the anticoagulant reversal drugs market, focusing on innovative treatments for managing anticoagulant-related complications. One of their key products is Andexanet alfa (brand name Andexxa), a reversal agent for factor Xa inhibitors like rivaroxaban and apixaban, designed to quickly counteract anticoagulant effects in emergencies.
• AstraZeneca: Provides a variety of products in the anticoagulant reversal drugs market, emphasizing innovative therapies for managing anticoagulant-related complications. Their notable product, idarucizumab (brand name Praxbind), specifically reverses the anticoagulant dabigatran by binding to it and neutralizing its effects rapidly, making it essential in emergencies.

 

Key Players

• Pfizer Inc
• AstraZeneca
• Dr. Reddy’s Laboratories Ltd
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Mylan N.V.
• Novartis AG
• Lupin
• Cipla Inc

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The anticoagulant reversal drugs market is set for significant growth, driven by the rising incidence of thromboembolic disorders and an aging population requiring anticoagulation therapy. The increasing need for effective reversal options during surgical procedures, along with heightened awareness of anticoagulant risks, positions this market for future expansion. Key players are actively pursuing strategies to enhance their offerings, ensuring they can meet the evolving healthcare landscape's demands effectively.

Antibodies Contract Manufacturing Market: Demand Drivers and Market Dynamics

 The global antibodies contract manufacturing market was valued at USD 17.79 billion in 2024 and is expected to reach USD 31.76 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.1% from 2025 to 2030. The increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics significantly drives this market growth.

 

These antibody therapies have demonstrated effectiveness in treating a range of conditions, including cancers, rheumatoid arthritis, and other chronic diseases, thereby boosting the demand for therapeutic antibody production. This rising demand is expanding the antibody contract manufacturing market as companies strive to scale production to meet the evolving needs of healthcare providers and patients.

 

Biopharmaceutical manufacturing is recognized as a leading sector with considerable growth potential. Many healthcare stakeholders believe this sector will emerge as one of the top 10 revenue generators in the coming years. Furthermore, market players are continuously advancing this sector to address the growing demand for bio-based pharmaceuticals, which is expected to lead to a surge in Contract Manufacturing Organizations (CMOs) for biopharmaceutical production. For example, in February 2024, Catalent's acquisition by Novo Holdings, along with the expansion of its European facilities, enhanced its antibody production capabilities, particularly targeting small molecules and biologics for advanced therapies. This expansion is in line with their strategy to augment therapeutic offerings, including cell and gene therapies, contributing to a robust product pipeline.

 

Key Market Trends & Insights

• North America: The antibody contract manufacturing market in North America led the global market in 2024, holding around 34.17% share. This dominance is due to extensive biopharmaceutical manufacturing in the region and the presence of numerous CDMO/CMO facilities. Legislation regarding biological development in the region is expected to significantly influence the progress of biopharmaceutical contract manufacturing.
• Product Segmentation: Monoclonal antibodies (mAbs) represented the largest product segment with a 76.42% share as of 2024. mAb formulations are increasingly preferred as targeted therapies for various lung conditions, including lung cancer, infections, and asthma.
• Source Segmentation: The mammalian source segment captured the largest market share at 57.52% in 2024. In response to the growing demand for antibody contract manufacturing services, several CMOs are expanding their mammalian cell culture production capacities. The mammalian cell expression system is favored for mAb production due to its ability to process, produce, and secrete complex molecules effectively.
• End Use Segmentation: The biopharmaceutical companies segment accounted for over 66.49% of the market share in 2024 and is projected to be the fastest-growing segment during the forecast period. These companies play a pivotal role in developing innovative treatments for patients globally.

 

Order a free sample PDF of the Antibodies Contract Manufacturing Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 17.79 Billion
• 2030 Projected Market Size: USD 31.76 Billion
• CAGR (2025-2030): 10.1%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

International partnerships are a vital strategy among market players. For instance, U.S. CMOs are increasingly collaborating with counterparts in the Swiss pharmaceutical sector. Additionally, the major CMOs are expanding to meet market demands and maintain a competitive edge.

 

Key Players

• Lonza
• Samsung Biologics
• WuXi Biologics.
• Charles River Laboratories
• FUJIFILM Holdings Corporation
• Boehringer Ingelheim Biopharmaceuticals GmbH
• AGC Biologics
• Cytovance Biologics, Inc.
• EMERGENT
• Thermo Fisher Scientific
• Labcorp Drug Development
• Catalent, Inc.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The antibodies contract manufacturing market is poised for substantial growth, driven by the increasing demand for therapeutic antibodies and the expansion of biopharmaceutical manufacturing capabilities. As companies adapt to meet the evolving needs of healthcare providers and patients, strategic collaborations and technological advancements will play crucial roles in shaping the future landscape of this dynamic market.

Analgesics Market: Impact of Opioid Regulations on Growth

 The global analgesics market size was valued at USD 38.60 billion in 2022 and is projected to reach USD 61.39 billion by 2030, growing at a CAGR of 6.02% from 2023 to 2030. The rise in incidences of arthritis and osteoarthritis, neuropathic diseases, and cancer is expected to drive market growth during the forecast period.

 

Additionally, the growing efforts of pharmaceutical companies to develop novel analgesics to manage pain and related disorders are anticipated to provide lucrative growth opportunities. For instance, as of October 2022, there were 17 novel pain relief drugs in development phases in the U.S., of which 16 were in phase 3 clinical trials. In May 2020, Assertio Holdings, Inc. merged with Zyla Life Sciences to enhance its pain management product portfolio.

 

The increasing prevalence of targeted diseases is expected to further propel market growth over the forecast period. According to the CDC, approximately 1 in 4 U.S. adults (23.7%), or about 58.5 million people, are diagnosed with arthritis. This condition is more prevalent in women compared to men, and its incidence increases with age.

 

Osteoarthritis is a leading form of arthritis, while fibromyalgia and gout are among the common rheumatic conditions. Common analgesics used in managing arthritis include celecoxib, naproxen, ibuprofen, diclofenac, and etodolac, among others. Therefore, the surge in the prevalence of arthritis serves as a major driving factor in the analgesics market.

 

Key Market Trends & Insights

• In 2022, North America led the global analgesics market with a revenue share of 31.76%. This dominance is attributed to the presence of several leading players engaging in various strategic initiatives, along with significant investments in analgesics-focused R&D in the region.
• By drug type, the non-opioid segment dominated the analgesics market, holding a share of 52.01% in 2022. This is due to the increasing demand for non-opioid analgesics, which have a lower risk of adverse effects, strong availability of generic preparations, and various initiatives by private organizations and governments promoting non-opioid options for pain management.
• By route of administration, the oral segment led the analgesics market with a share of 47.88% in 2022. Factors such as the convenient administration of analgesics via the oral route and its non-invasive nature significantly contribute to this segment’s market share.
• By application, the surgical and trauma segment held the largest share of 22.71% in the analgesics market in 2022. This high market share is due to the increasing demand for painkillers during and after surgeries, rising incidences of traumatic injuries, and various initiatives aimed at managing traumatic events.
• By distribution channel, the retail pharmacies segment dominated the analgesics market with a revenue share of 50.96% in 2022. The growth of this segment is attributed to the rising availability of OTC prescriptions, high penetration of generics, and the increasing number of analgesics prescriptions due to the growing incidence rate of pain and injuries.

 

Order a free sample PDF of the Analgesics Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2022 Market Size: USD 38.60 billion
• 2030 Projected Market Size: USD 61.39 billion
• CAGR (2023-2030): 6.02%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market in 2022

 

Key Companies & Market Share Insights

Key market players are implementing strategies such as new product development, mergers and acquisitions, and partnerships to expand their market share. For instance, in March 2023, Pfizer Inc. received U.S. FDA approval for its ZAVZPRET, the first CGRP receptor antagonist nasal spray for treating acute migraine in adults. Such initiatives are expected to propel market growth during the forecast period.

Key Players

• Bayer AG
• Endo International plc
• Assertio Holdings, Inc.
• Janssen Global Services, LLC
• GSK plc
• AbbVie Inc.
• Novartis AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The analgesics market is set for substantial growth, driven by the increasing prevalence of pain-related conditions and the ongoing development of innovative pain management solutions. The focus on non-opioid analgesics, along with strategic initiatives by key players, positions the market for continued expansion. As consumer demand rises and new treatments emerge, the analgesics market will likely evolve to meet the diverse needs of patients and healthcare providers.